Director/PDMR Shareholding

26 February 2021

4basebio UK Societas

(the "Company")

Director’s Dealing

4basebio UK Societas (AIM: 4BB), the specialist life sciences group focused on exploiting its intellectual property in the field of gene therapies and DNA vaccines, announces that, on 25 February 2021, Heikki Lanckriet, chief executive officer, acquired 3,000 ordinary shares at an average price of 345 pence per share on behalf of persons closely associated with him.

As a result of the acquisition of ordinary shares, Heikki Lanckriet’s beneficial holding, including shares held by persons closely associated with him, comprises 1,240,003 ordinary shares representing 10.07 per cent. of the Company’s issued share capital.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further enquiries, please contact:

4basebio UK Societas Heikki Lanckriet	[phone]
Nominated Adviser Cairn Financial Advisers LLP Jo Tuner / Sandy Jamieson	[phone]
Broker finnCap Ltd Geoff Nash/Richard Chambers/Charlotte Sutcliffe	[phone]

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Heikki Lanckriet
2	Reason for notification
a.	Position/Status	Chief Executive Officer
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	4basebio UK Societas
b.	LEI	2138005D5SAG8FIR6G91
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary Shares ISIN: GB00BLD8ZL39
b.	Nature of the transaction	Acquisition of ordinary shares
c.	Price(s) and volume(s)
			Volume(s)	Price (p)
			1,000 1,000 1,000	345p 345p 345p
d.	Aggregated information   - Aggregated Volume - Price	-3,000 -345 pence per share
e.	Date of the transaction	25/2/2021
f.	Place of the transaction	London Stock Exchange, AIM